Skip to main content

Table 4 Adverse events with suspected relationship to everolimus

From: Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors

  Everolimus 5 mg/day
(n = 12)
Everolimus 10 mg/day
(n = 12)
Adverse event, n (%) All grades Grade 3 Grade 4 All grades Grade 3 Grade 4
Total 12 (100) 3 (25.0) 0 12 (100) 3 (25.0) 0
Hyperglycemia 2 (16.7) 0 0 5 (41.7) 1 (8.3) 0
Fatigue 2 (16.7) 0 0 4 (33.3) 1 (8.3) 0
Anemia 1 (8.3) 1 (8.3) 0 3 (25.0) 0 0
Blood alkaline phosphatase increased 1 (8.3) 0 0 3 (25.0) 1 (8.3) 0
Thrombocytopenia 2 (16.7) 1 (8.3) 0 3 (25.0) 0 0
Hypokalemia 3 (25.0) 1 (8.3) 0 2 (16.7) 0 0
Upper respiratory tract infection 1 (8.3) 1 (8.3)   0 0 0